Climb Bio to Present at Upcoming Investor Conferences
Investors can watch Climb Bio’s conference presentations live via webcast and access 30-day replays through the Investors & Media section of its website.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Climb Bio (CLYM)/b) will participate in two upcoming investor healthcare conferences in September 2026 via fireside chats.Management will appear at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9 from 4:30–5:05 p.m. ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 from 8:30–9:05 a.m. ET. Live webcasts and 30-day replays will be available through the Investors & Media section of Climb Bio’s website.
Details
News Market Reaction – CLYM
On Sep 2, the day this news came out, CLYM closed 1.48% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day. Relative volume reached 4.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
Wells Fargo 21st Annual Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 9
Time: 4:30 – 5:05 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16
Time: 8:30 – 9:05 AM a.m. ET
The live webcasts will be accessible via the “Investors & Media” section of the Climb Bio website. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.